Increased IL-1␤, IL-8, and IL-17 mRNA Expression in Blood Mononuclear Cells Observed in a Prospective
Ischemic Stroke Study S troke is a major cause of human suffering, hospitalization, chronic disability, and death. There is increasing evidence that ischemic brain injury secondary to arterial occlusion is characterized by acute local inflammation. During reperfusion after acute ischemia, polymorphonuclear neutrophils (PMN) are believed to exacerbate tissue damage by both physical obstruction of vessels and release of oxygen radicals, proinflammatory cytokines, and cytolytic enzymes. 1 In animal models of cerebral ischemia, accumulation of PMN has been detected within the first 12 hours after induction of ischemia. 2 Tissue damage due to ischemic stroke can be reduced in experimental animal models by blockage of leukocyte accumulation. For instance, in knockout mice lacking the intercellular adhesion molecule-1 (ICAM-1) gene, which results in less PMN infiltration, the infarct volume was significantly reduced after transient middle cerebral artery occlusion compared with control animals. 3 Activated PMN produce cytokines, ie, low-molecular-weight proteins that mediate and regulate immune and inflammatory responses. Increased protein levels of proinflammatory cytokines such as tumor necrosis factor-␣ (TNF-␣) and interferon-␥ (IFN-␥) have been demonstrated in brain autopsies from patients after acute stroke compared with control brains from patients with other neurological diseases. 4 Increased production of several cytokines, including interleukin (IL)-1␤, IL-6, IL-8, IL-10, TNF-␣, and granulocyte-macrophage colony-stimulating factor, has been demonstrated intrathecally in patients with acute ischemic stroke. [5] [6] [7] Increased synthesis of cytokines in acute stroke is, however, not restricted to the central nervous system (CNS) but can also be detected systemically. 8 -10 Such cytokine abnormalities are of interest, because they may constitute a pathway for therapeutic intervention into the CNS.
Chemokines constitute a subgroup of the cytokine family, which may play a pivotal role in the accumulation of leukocytes to ischemic areas of the brain. 11 We have recently described that patients with acute ischemic stroke have a clear increase systemically of IL-8 mRNA expressing PBMC, as well as increased plasma levels of IL-8. 9 To further elucidate involvement of cytokines in ischemic stroke and thereby identify substances that perhaps could be targeted in future therapeutic studies, we examined mRNA expression by peripheral blood mononuclear cells (PBMC) of the chemokine macrophage inflammatory protein-1␣ (MIP-1␣), besides IL-8, and of the proinflammatory cytokines IL-1␤ and IL-17 over the first month after ischemic stroke. IL-8 is a potent chemoattractant for PMN both in vitro and in vivo, whereas MIP-1␣ mainly attracts mononuclear cells. [11] [12] [13] [14] IL-1␤ and IL-17 induce the production of IL-8 in endothelial and parenchymal cells, indicating an indirect role in PMN recruitment. 15, 16 To study the temporal profile of cytokine production after acute ischemic stroke, a prospective longitudinal study with repetitive blood sampling 1 to 31 days after stroke onset was performed in 29 patients with ischemic stroke. Cytokine mRNA expression was further correlated to neurological impairment, as measured by the Scandinavian Stroke Scale (SSS), at the acute stage (days 1 to 3 after onset of symptoms) and during follow-up (days 20 to 31).
Subjects and Methods

Patients
Twenty-nine consecutive patients with ischemic stroke, hospitalized at the Stroke Center of the Department of Neurology, Huddinge University Hospital (Huddinge, Sweden), were included in the study (Table 1) . Twenty-five patients had completed ischemic stroke, defined as clinical symptoms persisting for Ͼ24 hours, and 4 patients had Ն1 transient ischemic attacks (TIAs), defined as a complete recovery from clinical symptoms within 24 hours. 17 The diagnosis was based on clinical history and neurological examination. Two of the patients with ischemic stroke had symptoms confined to the vertebrobasilar territory, and the remaining 27 patients had symptoms from the carotid arterial territory. Brain CT was routinely performed in all stroke patients within 24 hours after their admission to the hospital. CT scans were normal in the patients with TIA. Well-defined hypodense areas, indicating ischemic lesions, were detected in all but 3 of the patients with completed ischemic stroke. Patients with clinical evidence of an acute infection, as well as patients with a history of malignancy, autoimmune disease, or myocardial infarction, were excluded from the study to avoid other potential sources of cytokine upregulation. Routine blood variables were assessed in all patients. None of the patients had increased blood leukocyte counts. From each patient, peripheral blood was obtained at 3 time points, ie, on days 1 to 3, 4 to 10, and 20 to 31 after onset of symptoms. From 19 of the stroke patients plasma and cerebrospinal fluid (CSF) were obtained on days 1 to 3, and plasma only was obtained on days 20 to 31 after stroke onset.
Peripheral blood was also obtained from 18 healthy volunteers, consisting of staff from the department (Table 1) . CSF and plasma samples were obtained from 17 patients with tension headache (Table 1) .
The study protocol was approved by the Ethics Committee of Karolinska Institutet at Huddinge University Hospital.
Preparation of Blood Mononuclear Cells
PBMC were obtained by density gradient centrifugation on Lymphoprep (Nycomed). The cells from the interphase were collected, washed twice with Dulbecco's modification of Eagle medium (Gibco), ultimately washed once with PBS and counted. Cell viability as measured by trypan blue exclusion always exceeded 95%. Aliquots containing 1ϫ10 5 PBMC were dried onto electrically charged microscope slides (SuperFrost/Plus, Menzel-Gläser). Slides were kept at Ϫ20°C until hybridization.
In Situ Hybridization to Detect IL-8, IL-1␤, IL-17, and MIP-1␣ mRNA in PBMC
In situ hybridization (ISH) was performed as previously described. 18 A mixture of 3 to 4 different synthetic oligonucleotide probes was used for each cytokine in order to increase the sensitivity of the method. The probes for IL-1␤, IL-8, and MIP-1␣ (R&D Systems) were 30 bases long, and the probes for IL-17 (KEBO) contained 48 bases. A constant guanine/cytosine ratio of approximately 60% was used. Following ISH, slides were rinsed in SSC, dehydrated through gradient ethanol, dipped in Kodak NTB2 emulsion, and exposed at 4°C for 14 days. The emulsion-coated slides were developed in D19 (Kodak) and fixed in Unifix (Kodak). As negative control probe, the sense sequence to bases 4641 to 4688 of human IFN-␥ was used in parallel, without revealing any positive cells. Previous studies from our laboratory have revealed no binding to the sense probes of IL-8, IL-1␤, IL-17, and MIP-1␣, and were therefore not used. Coded slides were examined by dark field microscopy for positive cells containing Ͼ15 grains per cell in a starlike distribution. The intracellular distribution of the grains was always checked by light microscopy at higher magnification. The number of cells used for ISH was not equal to the number of cells ultimately detected on the slides. To compensate for cell losses, the total numbers of cells on the slides were counted. Cell losses varied between 10% and 50% from cell application to cell counting. The preferential loss of certain cell types is not ruled out. Positive cells practically always contained Ͼ15 (usually 50 to 100) grains in a starlike distribution, whereas negative cells contained no or few grains, which were then scattered randomly over the cell and not distributed in a starlike fashion. Consequently, it was easy to differentiate between cytokine mRNA positive and negative cells.
ELISA for the Determination of IL-8 Levels in Peripheral Blood and CSF
Peripheral blood was collected in tubes containing EDTA and centrifuged within 30 minutes at 1500g for 10 minutes at 4°C. Plasma and CSF supernatants were immediately frozen at Ϫ20°C. The IL-8 ELISA was performed according to the manufacturer's instructions (Biosource International). The detection limit was 0.39 pg/mL. Plasma and CSF samples were examined in duplicate.
Statistical Analysis
Friedman nonparametric repeated-measures test was used to compare cytokine mRNA expression in stroke patients at different time points. The nonparametric Mann-Whitney test adjusted for multiple comparisons according to Bonferroni was used to compare cytokine mRNA expression in stroke and healthy individuals. Wilcoxon signed rank test for pairs were used for 2-group comparisons of the IL-8 levels in plasma and CSF. Correlations between IL-8 mRNA expressing PBMC and IL-8 plasma levels and between cytokine 
Kostulas et al IL-1␤, IL-8, and IL-17 in Stroke 2175
mRNA expressing PBMC and SSS scores were examined by Spearman rank correlation test. Reported probability value are 2 tailed, and PϽ0.05 was considered statistically significant. After adjustment to Bonferroni, PϽ0.01 was considered significant in the Mann-Whitney analysis.
Results
IL-8 mRNA Expressing PBMC
Most patients with ischemic stroke had high numbers of IL-8 mRNA expressing PBMC regardless of the time interval between onset of clinical symptoms and examination. When examined during the acute phase, ie, 1 to 3 days after onset of symptoms, 26 of 29 patients (90%) with ischemic stroke had elevated numbers of IL-8 mRNA expressing PBMC when defined as Ͼ(meanϩ2SD) of the numbers encountered in the healthy volunteers (PϽ0.0001). The highest numbers of IL-8 mRNA expressing PBMC were observed 1 to 3 days after onset of symptoms, with a tendency for lower numbers already at days 4 to 10 (Table 2; Figure 1 ). During clinical follow-up 20 to 31 days after onset, the numbers of IL-8 mRNA expressing PBMC were significantly lower than in the acute phase (PϽ0.001) but still remained elevated compared with those in the group of healthy volunteers (PϽ0.0001).
IL-8 Concentrations in CSF and Plasma
Soluble IL-8 was detected in CSF and plasma 1 to 3 days after onset of symptoms in all 19 examined patients with acute ischemic stroke ( Table 3 ). The IL-8 concentrations were increased in both CSF (PϽ0.0001) and plasma (PϽ0.001) in patients examined 1 to 3 days after onset of stroke compared with concentrations in patients with tension headache. Concentrations of IL-8 were higher in CSF than plasma in the group of patients with ischemic stroke (PϽ0.0001) as well as tension headache (PϽ0.001; Figure 2 ). At follow-up 20 to 31 days after onset of ischemic stroke, IL-8 concentrations in plasma were lower (PՅ0.01) than during the acute stage at days 1 to 3. A positive correlation between numbers of IL-8 mRNA expressing PBMC and plasma concentrations of IL-8 was observed in 19 patients with ischemic stroke from whom both blood and plasma samples were available (rϭ0.7; PϽ0.00001).
IL-1␤b and IL-17 mRNA Expressing PBMC
The temporal profiles of levels of IL-1␤ and IL-17 mRNA expressing PBMC after stroke onset were similar to that observed for IL-8 mRNA-positive PBMC (Table 2) . Thus, the highest numbers of PBMC expressing IL-1␤ and IL-17 mRNA were found 1 to 3 days after onset of symptoms, followed by decreasing numbers during follow-up (Table 2 ; Figure 1 ). IL-8, IL-1␤, MIP-1␣, and IL-17 Twenty-three of 29 patients (79%) with ischemic stroke had elevated numbers of IL-1␤ mRNA expressing PBMC when defined as Ͼ(meanϩ2SD) of the numbers encountered in the healthy subjects at days 1 to 3 (PϽ0.0001). At follow-up 20 to 31 days after stroke onset, the numbers of IL-1␤ mRNA were lower compared with those at 1 to 3 days after onset (PϽ0.0001), and no differences in numbers of IL-1␤ mRNA expressing PBMC could be detected between patients with ischemic stroke examined 20 to 31 days after onset and the group of healthy volunteers ( Table 2) .
Seventeen of 29 patients (59%) with ischemic stroke had elevated numbers of IL-17 mRNA expressing PBMC defined as Ͼ(meanϩ2SD) of the numbers encountered in the healthy subjects at days 1 to 3 (PϽ0.0001). Similarly to IL-1␤ mRNA expression, numbers of IL-17 mRNA expressing PBMC were at follow-up 20 to 31 days after stroke onset lower compared with 1 to 3 days after onset (PϽ0.0001), and no differences in numbers of IL-17 mRNA expressing PBMC could be detected between patients with ischemic stroke examined 20 to 31 days after onset and the group of healthy volunteers ( Table 2) .
MIP-1␣ mRNA Expressing PBMC
No differences in numbers of MIP-1␣ mRNA expressing PBMC were observed between the patients with ischemic stroke and the group of healthy volunteers at any time point (Table 2 ). There was a tendency for increasing numbers of MIP-1␣ mRNA expressing PBMC during follow-up after ischemic stroke, but the differences were small and did not reach statistical significance (Table 2; Figure 1 ).
Correlation Between Neurological Impairment and Numbers of Cytokine mRNA Expressing PBMC
The degree of neurological impairment was estimated in all patients with ischemic stroke according to the SSS at inclusion and follow-up 20 to 31 days after onset of symptoms. 19 The SSS scores ranged between 8 and 58 (median 28) at inclusion and between 12 and 58 (median 53) 20 to 31 days after onset of symptoms.
Ischemic stroke patients with a high degree of neurological impairment (ie, a low SSS score) had high numbers of PBMC expressing IL-8, IL-1␤, and IL-17 mRNA at inclusion (Figure 3) . There was an inverse correlation between SSS scores registered 1 to 3 days after onset of symptoms and numbers of IL-8 (rϭϪ0.5; PϽ0.01), IL-1␤ (rϭϪ0.5; PϽ0.01), and IL-17 (rϭϪ0.5; PϽ0.01) mRNA expressing PBMC.
For IL-8 and IL-1␤, the inverse correlation between numbers of cytokine mRNA expressing PBMC and SSS scores still remained significant (IL-8: rϭϪ0.5, PϽ0.01; IL-1␤: rϭϪ0.4, PϽ0.05) at follow-up 20 to 31 days after onset. The numbers of MIP-1␣ mRNA expressing PBMC did not correlate to the degree of neurological impairment as measured by the SSS at any of the time points examined.
Discussion
PMN infiltrating postischemic tissue are considered to contribute to disability after cerebral ischemia. 20 Identification of factors involved in the selective recruitment and accumulation of inflammatory cells into ischemic brain tissue is likely to expand our understanding of the mechanisms that result in transient or permanent neurological deficits. The mechanisms behind the entry of leukocytes to sites of ischemia are incompletely understood. Locally produced proinflammatory cytokines such as TNF-␣, IL-1␤, and IL-6 are thought to initiate the inflammatory process. TNF-␣ and IL-1␤ mRNA and protein are, for instance, elevated in the brain after experimental middle cerebral artery occlusion. 21, 22 Astrocytes and endothelial cells can respond in vitro to such proinflammatory cytokines with enhanced expression of chemokines, which results in the influx of leukocytes to areas of inflammation. 23 Increased concentrations of the CXC chemokine IL-8 can be detected intrathecally in patients with ischemic stroke. 7 Enhanced synthesis of IL-8 is, however, not restricted to the CNS. We have previously demonstrated elevated levels of IL-8 mRNA expressing PBMC in patients with acute ischemic stroke, 9 an observation confirmed in the present study. This upregulation of IL-8 mRNA expression occurred early, ie, already within the first few days after onset of symptoms, and remained elevated during the observation time of up to 1 month. IL-8 is a potent chemoattractant that has been demonstrated to recruit PMN in vivo. 12, 14 Besides attracting PMN, IL-8 can also stimulate the release of neutrophil granules and the respiratory burst of these cells. 24 -26 Degranulation of PMN is accompanied by upregulation of complement receptors and integrins on their cell membranes, facilitating cell adhesion. 27 A recent study demonstrated that IL-8 can also delay PMN apoptosis, indicating that IL-8 can further prolong and amplify the effects of PMN. 28 In the present study, we found that the proinflammatory cytokines IL-1␤ and IL-17 were also elevated systemically after ischemic stroke. IL-17 induces the secretion of cytokines, including IL-8, and enhances the expression of ICAM-1 in cultures of stromal cells and human fibroblasts. 15, 29 IL-1␤ may be indirectly involved in the recruitment of inflammatory cells through the induction of increased IL-8 production. 16 Interestingly, administration of a human IL-1 receptor antagonist has been shown to reduce postischemic injury in murine studies of cerebral ischemia, as reflected by reduced numbers of necrotic neurons, and of leukocytes in the ischemic brain and a decreased area of pallor. 30, 31 Concentrations of IL-8 were higher in CSF compared with plasma in the patients with ischemic stroke, indicating that IL-8 is predominantly produced within the CNS, probably at the site of the damaged tissue. In response to focal ischemia, a multitude of genes show an increased expression. Activated brain endothelial cells at the site of inflammation, representing the front line of the blood-brain barrier, secrete cytokines such as TNF-␣, IL-1␤, IL-6, and IL-8, and express adhesion molecules such as ICAM-1, ELAM-1, and P-selectin. 32 These stimuli might activate PBMC and result in the expression of cytokines and chemokines, as observed in this study. After CNS injury the blood-brain barrier becomes leaky, which facilitates the entry of activated circulating immune cells into the CNS. [33] [34] [35] It is, however, still not clear whether resident cells in the CNS, activated PBMC, or both are the main producers of cytokines. A strong systemic response, as measured by increased numbers of PBMC expressing mRNA for IL-8 as well as IL-1␤ and IL-17, may indicate a possible role for systemic cells contributing to intrathecal production of cytokines.
Increased expression of cytokines in PBMC may not necessarily contribute to CNS injury but may instead represent secondary epiphenomena to tissue damage. Alternatively, an inflammatory process distal from the CNS occurring in relation to the ischemic event, eg, concomitant infections, may result in increased activation of the PBMC. In this study, however, patients with clinical or laboratory evidence of any infection were excluded. Also, psychological stress may result in increased activation of the PBMC. The mechanism of stress-related increases in cytokine production remains unclear. Hypothetically, autonomic involvement, catecholamines, and neuropeptides may either alone or in combination play a role in activating PBMC. 36 It is not clear whether affecting the production of cytokines by circulating PBMC reduces tissue damage. In a rabbit model of cerebral reperfusion injury, systemic administration of monoclonal antibodies against IL-8 at the initiation of reperfusion prevented PMN infiltration and reduced the size of brain edema at 6 hours and infarction at 12 hours after reperfusion. 37 Further studies in the MCAO model will define a functional role for systemic therapeutic intervention with anticytokine monoclonal antibodies, receptor antagonists, or cytokine inducers in the treatment of stroke.
In conclusion, increased numbers of cells expressing IL-8, IL-1␤, and IL-17 mRNA were observed systemically in ischemic stroke patients, with highest levels within 1 to 3 days after onset of symptoms. IL-8 mRNA expression remained elevated at follow-up after 20 to 31 days, when levels of IL-1␤ and IL-17 had returned to levels registered in healthy individuals. Numbers of IL-8 and IL-1␤ mRNA expressing PBMC correlated with the severity of the ischemic event, as measured by the SSS. Systemic upregulation of cytokine expression may contribute to the pathogenesis of ischemic stroke through a potentiation of the secondary inflammatory process.
